URGENT:COVID prophylaxis | Vitamin D | Latest research | NIH | CDC | Worldometer
Information about Nateglinide
Nateglinide is an oral hypoglycemic agent and amino acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabetes.
Liver safety of Nateglinide
Nateglinide has been linked to rare instances of clinically apparent acute liver injury.
Mechanism of action of Nateglinide
Nateglinide (na teg' li nide) is an insulin secretagogue that is similar in action but different in structure from the sulfonylureas. It is a derivative of phenylalanine and stimulates insulin secretion by blocking ATP sensitive potassium channels in pancreatic beta-cells, causing cell membrane depolarization which results in calcium influx and insulin secretion. Nateglinide has been shown to reduce the postprandial increase in glucose in patients with type 2 diabetes and improve glycemic control. Nateglinide
FDA approval information for Nateglinide
Nateglinide was approved for use in the United States in 2000.
Clinical use of Nateglinide
The current indications are for management of type 2 diabetes used in combination with diet and exercise, with or without other oral hypoglycemic agents. Nateglinide is available generically and under the brand name Starlix in tablets of 60 and 120 mg.
Dosage and administration for Nateglinide
The typical initial dose in adults is 120 mg three times daily before meals.
Side effects of Nateglinide
- Alpha-Glucosidase Inhibitors
- Incretin-Based Drugs
- Metiglinide Analogues
- Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitors